Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

French artificial heart maker Carmat targets break-even in 2027

By Dina Kartit

(Reuters) -French artificial heart maker Carmat expects to break-even in 2027, it said on Monday, as it gradually resumes implants and faces strong demand in Europe ahead of its commercial launch in the United States.

The Aeson implant maker, which targets a U.S. launch in 2026, plans to lift its production to 100 hearts in 2023 and further accelerate to 500 in 2024 and 1,000 in 2027.

“Strong interest in, and demand for Aeson make us particularly confident about the development of our sales,” Carmat’s Chief Executive Officer Stephane Piat said in a statement.

Providing financial targets for the first time, Carmat told investors and reporters it saw total addressable market exceeding $40 billion by 2030, with over 200,000 potential patients per year in Europe and the United States. That could generate over $1 billion in annual revenue for the company over the next 10 years.

This year, Carmat expects sales of 10-13 million euros ($10.9-14.1 million), following the resumption of commercial implants of Aeson in November.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

The company, which raised 31.1 million euros via a share issue last month, had to suspend implants late in 2021 following a quality issue affecting some of its prostheses.

It aims to have 30 commercially operational hospitals across Europe and reaffirmed its efforts for the complete reimbursement of the Aeson therapy in Europe, particularly in France, within the framework of a clinical study.

Carmat annual results are due on Feb. 23.

($1 = 0.9216 euros)

(Reporting by Dina Kartit Editing by Sharon Singleton and Tomasz Janowski)


Recent Post: